Skip to Content
Merck

Esters of valerenic acid as potential prodrugs.

European journal of pharmacology (2014-04-01)
Juliane Hintersteiner, Maximilian Haider, Denise Luger, Christoph Schwarzer, Gottfried Reznicek, Walter Jäger, Sophia Khom, Marko D Mihovilovic, Steffen Hering
ABSTRACT

Valerenic acid (VA) is a β2/3 subunit-specific modulator of γ-aminobutyric acid (GABA) type A (GABAA) receptors inducing anxiolysis. Here we analyze if VA-esters can serve as prodrugs and if different ester structures have different in vitro/in vivo effects. Modulation of GABAA receptors expressed in Xenopus oocytes was studied with 2-microelectrode-voltage-clamp. Anxiolytic effects of the VA-esters were studied on male C57BL/6N mice by means of the elevated plus maze-test; anticonvulsant properties were deduced from changes in seizure threshold upon pentylenetetrazole infusion. VA was detected in plasma confirming hydrolysis of the esters and release of VA in vivo. Esterification significantly reduced the positive allosteric modulation of GABAA (α1β3γ2S) receptors in vitro. in vivo, the studied VA-ester derivatives induced similar or even stronger anxiolytic and anticonvulsant action than VA. While methylation and propylation of VA resulted in faster onset of anxiolysis, the action of VA-ethylester was longer lasting, but occurred with a significant delay. The later finding is in line with the longer lasting anticonvulsant effects of this compound. The estimated VA plasma concentrations provided first insight into the release kinetics from different VA-esters. This might be an important step for its future clinical application as a potential non-sedative anxiolytic and anticonvulsant.

MATERIALS
Product Number
Brand
Product Description

Valerenic acid, primary reference standard
Supelco
Valerenic acid, analytical standard
Valerian standardised dry extract, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Acetylvalerenolic acid, ≥95% (LC/MS-ELSD)